AMCo is delighted to announce the acquisition of Primegen Limited ("Primegen"), a speciality pharma business in the UK. Primegen sells a number of niche medicines, predominantly in the UK, and has an attractive pipeline of UK and international registrations.
The acquisition of Primegen is in keeping with AMCo's strategy of identifying niche medicines and opportunities to expand its sales base throughout AMCo's growing international platform. AMCo currently sells its products in 112 territories worldwide. Since the acquisition of Fucithalmic(r) from LEO Pharma in April 2013, AMCo has acquired or set up European commercial platforms in the Nordics, Benelux and France, and has opened offices in Dubai to develop its growing MENA presence. AMCo has also established a presence in South Africa, Hong Kong and Argentina to manage its regional African, AsiaPac and Latin America businesses respectively.
John Beighton, Chief Executive of AMCo, commented: "I am delighted with this opportunity to bring a number of Primegen's products into the AMCo portfolio of niche medicines, and to make them available to patients globally through AMCo's international sales network. This acquisition represents a further step in AMCo's growth as an international niche pharma company."
Anil Sharma, CEO of Primegen, commented: "This acquisition by AMCo is a positive step forwards which will enable many of Primegen's products to be made available internationally faster and more efficiently than Primegen could have done, which is very exciting for us."